International Journal of Hematology

, Volume 73, Issue 4, pp 469–475 | Cite as

Targeted Integration of Foreign DNA Into a Defined Locus on Chromosome 19 in K562 Cells Using AAV-Derived Components

  • Katsuhiro Kogure
  • Masashi Urabe
  • Hiroaki Mizukami
  • Akihiro Kume
  • Yuko Sato
  • John Monahan
  • Keiya Ozawa
Rapid Communication


Targeted integration of foreign DNA is ideal for gene therapy, particularly when target cells such as hematopoietic cells actively divide and proliferate. Adeno-associated virus (AAV) has been shown to integrate its genome into a defined locus, AAVS1 (19q13.3-qter). The inverted terminal repeat (ITR) and Rep proteins are responsible for this site-specific integration, and a system has been developed that delivers a gene preferentially into AAVS1 by using these components of AAV. We examined whether this system could be applied to gene transfer into K562 cells. Tworep expression plasmids were tested, 1 driven by the cytomegalovirus (CMV) promoter (pCMVR78) and the other under the translational control of an internal ribosome entry site (pMGiR78) with mouse mammary tumor virus promoter. K562 cells were cotransfected with arep plasmid and a plasmid containing aneo gene flanked by the ITRs. G418-resistant clones were isolated and analyzed by Southern blot analysis and fluorescence in situ hybridization (FISH). Southern blot analysis suggested AAVS1-specific integration of theneo gene in 6 (35%) of 17 clones when K562 cells were transfected with pMGiR78 by lipofection. FISH located theneo gene on chromosome 19 in 5 of these 6 clones (29%). Eight (32%) of 25 clones obtained by electroporation with pCMVR78 had theneo gene at AAVS1, according to Southern blot analysis, and 4 of these 8 clones (16%) were positive according to FISH analysis. These results suggest that site-specific integration of foreign DNA can be achieved at a significantly high rate in human hematopoietic cells using the A AV components.

Key words

Adeno-associated virus ITR Rep protein AAVS1 locus Targeted integration K562 cells 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kume A, Hanazono Y, Mizukami H, et al. Hematopoietic stem cell gene therapy: a current overview.Int J Hematol. 1999;69:227–233.PubMedGoogle Scholar
  2. 2.
    Verma IM, Somia N. Gene therapy: promises, problems and prospects [news].Nature. 1997;389:239–242.CrossRefPubMedGoogle Scholar
  3. 3.
    Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.Science. 1996;272:263–267.CrossRefPubMedGoogle Scholar
  4. 4.
    Smith AE. Viral vectors in gene therapy.Annu Rev Microbiol. 1995;49:807–838.CrossRefPubMedGoogle Scholar
  5. 5.
    Russell DW, Kay MA. Adeno-associated virus vectors and hematology.Blood. 1999;94:864–874.PubMedCentralPubMedGoogle Scholar
  6. 6.
    Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specific integration by adeno-associated virus.Proc Natl Acad Sci U S A. 1990;87:2211–2215.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kotin RM, Menninger JC, Ward DC, et al. Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter.Genomics. 1991;10:831–834.CrossRefPubMedGoogle Scholar
  8. 8.
    Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associ-ated virus DNA by non-homologous recombination.EMBO J. 1992;11:5071–5078.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Samulski RJ, Zhu X, Xiao X, et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19.EMBO J. 1991;10:3941–3950.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Linden RM, Ward P, Giraud C, et al. Site-specific integration by adeno-associated virus.Proc Natl Acad Sci U S A. 1996;93:11288–11294.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Weitzman MD, Kyöstio SR, Kotin RM, et al. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA.Proc Natl Acad Sci U S A. 1994;91:5808–5812.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Surosky RT, Urabe M, Godwin SG, et al. Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome.J Virol. 1997;71:7951–7959.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Kearns WG, Afione SA, Fulmer SB, et al. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line.Gene Ther. 1996;3:748–755.PubMedGoogle Scholar
  14. 14.
    Yang CC, Xiao X, Zhu X, et al. Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro.J Virol. 1997;71:9231–9247.PubMedCentralPubMedGoogle Scholar
  15. 15.
    Fisher Adams G, Wong KK Jr, Podsakoff G, et al. Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction.Blood. 1996;88:492–504.Google Scholar
  16. 16.
    Zhou SZ, Cooper S, Kang LY, et al. Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood.J Exp Med. 1994;179:1867–1875.CrossRefPubMedGoogle Scholar
  17. 17.
    Goodman S, Xiao X, Donahue RE, et al. Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells.Blood. 1994;84:1492–1500.PubMedGoogle Scholar
  18. 18.
    Malik P, McQuiston SA, Yu XJ, et al. Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line.J Virol. 1997;71:1776–1783.PubMedCentralPubMedGoogle Scholar
  19. 19.
    Balague C, Kalla M, Zhang WW. Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome.J Virol. 1997;71:3299–3306.PubMedCentralPubMedGoogle Scholar
  20. 20.
    Pieroni L, Fipaldini C, Monciotti A, et al. Targeted integration of adeno-associated virus-derived plasmids in transfected human cells.Virology. 1998;249:249–259.CrossRefPubMedGoogle Scholar
  21. 21.
    Shelling AN, Smith MG. Targeted integration of transfected and infected adeno-associated virus vectors containing the neomycin resistance gene.Gene Ther. 1994;1:165–169.PubMedGoogle Scholar
  22. 22.
    McCarty DM, Christensen M, Muzyczka N. Sequences required for coordinate induction of adeno-associated virus p19 and p40 promoters by Rep protein.J Virol. 1991;65:2936–2945.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Urabe M, Hasumi Y, Kume A, et al. Charged-to-alanine scanning mutagenesis of the N-terminal half of adeno-associated virus type 2 Rep78 protein.J Virol. 1999;73:2682–2693.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Giraud C, Winocour E, Berns KI. Site-specific integration by adeno-associated virus is directed by a cellular DNA sequence.Proc Natl Acad Sci U S A. 1994;91:10039–10043.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Hermonat PL. Down-regulation of the human c-fos and c-myc proto-oncogene promoters by adeno-associated virus Rep78.Cancer Lett. 1994;81:129–136.CrossRefPubMedGoogle Scholar
  26. 26.
    Hermanns J, Schulze A, Jansen-Dürr P, et al. Infection of primary cells by adeno-associated virus type 2 results in a modulation of cell cycle-regulating proteins.J Virol. 1997;71:6020–6027.PubMedCentralPubMedGoogle Scholar
  27. 27.
    Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, et al. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector.J Virol. 2000;74:2567–2583.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2001

Authors and Affiliations

  • Katsuhiro Kogure
    • 1
    • 2
  • Masashi Urabe
    • 1
    • 2
  • Hiroaki Mizukami
    • 1
    • 2
  • Akihiro Kume
    • 1
    • 2
  • Yuko Sato
    • 3
  • John Monahan
    • 4
  • Keiya Ozawa
    • 1
    • 2
    • 5
    • 6
  1. 1.Division of Genetic TherapeuticsCenter for Molecular Medicine, Jichi Medical SchoolTochigi
  2. 2.CREST, Japan Science and Technology CorporationTochigi
  3. 3.Department of Intractable DiseasesResearch Institute, International Medical Center of JapanTokyoJapan
  4. 4.Avigen, Inc.AlamedaUSA
  5. 5.Division of Hematology, Department of MedicineJichi Medical SchoolTochigiJapan
  6. 6.Division of Genetic TherapeuticsCenter for Molecular Medicine, Jichi Medical SchoolTochigiJapan

Personalised recommendations